Gunning for Biogen’s multibillion dollar market, Eli Lilly cuts up another batch of Alzheimer’s data
Eli Lilly executives have their eyes set on Biogen’s multibillion-dollar Alzheimer’s market.
On Thursday, the Indianapolis pharma tried to bolster its case to win accelerated approval for its amyloid-clearing antibody donanemab with a pair of new presentations at the Alzheimer’s Association International Conference.
Most notably, they argued that data from their Phase II trial showed that the more patients’ amyloid levels fell, the better they did cognitively. There was, they wrote, a “direct relationship between decrease in amyloid plaque and slowing in disease progression rate.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.